Hyperion Therapeutics Inc (HPTX) financial statements (2021 and earlier)
Company profile
| Business Address |
2000 SIERRA POINT PARKWAY BRISBANE, CA 94005 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| SIC | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete financial analysis Financial benchmarking |
Balance sheet (Statement of financial position) ($ in millions)
| 12/31/2014 | 12/31/2013 | 12/31/2012 | |||
|---|---|---|---|---|---|
| ASSETS | |||||
| Current Assets | |||||
| Cash, cash equivalents, and short-term investments | 137 | 102 | 50 | ||
| Cash and cash equivalents | 103 | 74 | 50 | ||
| Short-term investments | 34 | 28 | |||
| Receivables | 15 | 4 | |||
| Inventory, net of allowances, customer advances and progress billings | 5 | 4 | ✕ | ||
| Inventory | 5 | 4 | |||
| Prepaid expense and other current assets | ✕ | ✕ | 1 | ||
| Other undisclosed current assets | 3 | 1 | |||
| Total current assets: | 159 | 112 | 51 | ||
| Noncurrent Assets | |||||
| Property, plant and equipment | 1 | 1 | 0 | ||
| Long-term investments and receivables | 9 | 16 | |||
| Long-term investments | 9 | 16 | |||
| Intangible assets, net (including goodwill) | 9 | 13 | ✕ | ||
| Intangible assets, net (excluding goodwill) | 9 | 13 | |||
| Other noncurrent assets | 2 | 1 | ✕ | ||
| Prepaid expense and other noncurrent assets | ✕ | ✕ | 0 | ||
| Total noncurrent assets: | 21 | 31 | 0 | ||
| TOTAL ASSETS: | 180 | 143 | 51 | ||
| LIABILITIES AND EQUITY | |||||
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 35 | 19 | 6 | ||
| Accounts payable | 5 | 2 | 2 | ||
| Accrued liabilities | 26 | 12 | 3 | ||
| Employee-related liabilities | 4 | 4 | 1 | ||
| Taxes payable | 1 | 0 | |||
| Debt | 6 | 4 | |||
| Deferred revenue and credits | 0 | ||||
| Other undisclosed current liabilities | (5) | (5) | (1) | ||
| Total current liabilities: | 30 | 20 | 9 | ||
| Noncurrent Liabilities | |||||
| Long-term debt and lease obligation | 18 | 3 | 8 | ||
| Long-term debt, excluding current maturities | 18 | 3 | 8 | ||
| Liabilities, other than long-term debt | 0 | 0 | |||
| Deferred revenue and credits | 0 | 0 | |||
| Total noncurrent liabilities: | 18 | 3 | 8 | ||
| Total liabilities: | 49 | 23 | 17 | ||
| Stockholders' equity | |||||
| Stockholders' equity attributable to parent | 132 | 120 | 34 | ||
| Common stock | 0 | 0 | 0 | ||
| Additional paid in capital | 260 | 242 | 173 | ||
| Accumulated other comprehensive loss | (0) | (0) | |||
| Accumulated deficit | (129) | (122) | (139) | ||
| Total stockholders' equity: | 132 | 120 | 34 | ||
| TOTAL LIABILITIES AND EQUITY: | 180 | 143 | 51 | ||
Income statement (P&L) ($ in millions)
| 12/31/2014 | 12/31/2013 | 12/31/2012 | ||
|---|---|---|---|---|
| Revenues (Revenue, Net) | 114 | 42 | ||
| Cost of revenue | (14) | (7) | ||
| Gross profit: | 100 | 35 | ||
| Operating expenses | (118) | (56) | (29) | |
| Other undisclosed operating income | 14 | 7 | ||
| Operating loss: | (4) | (13) | (29) | |
| Nonoperating income (expense) | (0) | 1 | (0) | |
| Investment income, nonoperating | 1 | 0 | 0 | |
| Other nonoperating income (expense) | (1) | 1 | (0) | |
| Interest and debt expense | (1) | (2) | (4) | |
| Loss from continuing operations before equity method investments, income taxes: | (5) | (14) | (32) | |
| Other undisclosed income (loss) from continuing operations before income taxes | (1) | 31 | ||
| Income (loss) from continuing operations before income taxes: | (6) | 17 | (32) | |
| Income tax expense | (0) | (0) | ||
| Net income (loss) available to common stockholders, diluted: | (6) | 17 | (32) | |
Comprehensive Income ($ in millions)
| 12/31/2014 | 12/31/2013 | 12/31/2012 | ||
|---|---|---|---|---|
| Net income (loss): | (6) | 17 | (32) | |
| Other comprehensive income (loss) | 0 | (0) | ||
| Comprehensive income (loss), net of tax, attributable to parent: | (6) | 17 | (32) | |
Statements sources
The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.